Navigation Links
Are intravenous treatments safe? New research raises doubts
Date:8/31/2009

German scientists have identified a serious and previously misunderstood contaminant that brings the safety and efficacy of intravenous treatments into question. In a report published in the September 2009 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org), they show how a common intravenous treatment used to boost blood pressure in ailing patients also contains substances called "advanced glycation end products," which trigger inflammation. These substances result from reactions that occur among the various proteins (called "posttranslational modification") within the intravenous fluid after it has been formulated for use. This study directly challenges today's prevalent belief that advanced glycation end products are not contaminants.

"Improving the quality of infusion solutions by accounting for posttranslational modification of proteins could lead to better clinical outcomes for patients, such as those treated solutions containing albumin," said Angelika Bierhaus, senior scientist and co-study author from the University of Heidelberg in Germany.

To make their discovery, Bierhaus and colleagues detected advanced glycation end products in several currently available albumin infusion solutions and injected separate groups of mice with solutions containing both high and low amounts of this substance. The mice receiving the high levels of advanced glycation end products experienced significantly higher inflammation and death rates than the mice receiving solutions with low levels of advanced glycation end products. This suggests that screening infusion solutions for posttranslational protein modifications and then removing the compounds may improve patient outcomes, especially treatments requiring albumin infusions.

"It is always difficult to learn that what was once thought safe might have more risk than previously appreciated, especially when it relates to treatments meant to save lives," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "This discovery, however, should allow manufacturers to improve the quality, tolerability and safety of a number of clinical products."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
2. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
3. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
4. New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. New Bill Offers Medicare Reimbursement Fix for Intravenous Immune Globulin
7. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
8. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
9. Drug-free treatments offer hope for older people in pain
10. Updated Brochure on Gynecologic Cancer Treatments Now Available
11. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/25/2017)... ... 2017 , ... FCPX users now have the ability to sharpen a desired ... Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical ... tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – ... Private has initiated a second print-run of its lavish luxury travel coffee table book. ... open, weighs in at more than six kilos, retails at EUR 1,000 per copy ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of ... critically important that we all are aware of our options and are empowered ... to announce the launch of its newest edition of "Vision and Hearing" in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis ... global Hemophilia market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology: